Cancer Network
By Michael Kaufman | 12 de diciembre de 2012
"ARRY-520, a novel selective kinesin spindle protein (KSP) inhibitor, showed promising clinical activity both alone and combined with low-dose dexamethasone in a phase II clinical trial in patients with relapsed and refractory multiple myeloma. Findings were reported by Jatin J. Shah, MD, of the department of lymphoma/myeloma at the University of Texas MD Anderson Cancer Center in Houston."..
leer mas en.
http://www.cancernetwork.com/conference ... 65/2119650
